Tick-borne encephalitis (inactivated) vaccine Interactions
There are 298 drugs known to interact with tick-borne encephalitis (inactivated) vaccine, along with 1 disease interaction. Of the total drug interactions, 1 is major, 295 are moderate, and 2 are minor.
Medications known to interact with tick-borne encephalitis (inactivated) vaccine
Note: Showing generic names only.
A
- abatacept
- abemaciclib
- abrocitinib
- acalabrutinib
- adalimumab
- afamitresgene autoleucel
- aldesleukin
- alefacept
- alemtuzumab
- allogeneic processed thymus tissue
- altretamine
- anakinra
- anifrolumab
- anti-thymocyte globulin (rabbit)
- asciminib
- asparaginase escherichia coli
- atezolizumab
- atidarsagene autotemcel
- avapritinib
- avelumab
- axicabtagene ciloleucel
- azacitidine
- azathioprine
B
- baricitinib
- basiliximab
- belantamab mafodotin
- belatacept
- belimumab
- belinostat
- bendamustine
- betamethasone
- bexarotene
- bimekizumab
- bleomycin
- blinatumomab
- bortezomib
- bosutinib
- brentuximab
- brexucabtagene autoleucel
- brigatinib
- brodalumab
- budesonide
- busulfan
C
- cabazitaxel
- canakinumab
- capecitabine
- carboplatin
- carfilzomib
- carmustine
- cemiplimab
- certolizumab
- chlorambucil
- chloramphenicol
- ciltacabtagene autoleucel
- cisplatin
- cladribine
- clofarabine
- cobimetinib
- copanlisib
- corticorelin
- corticotropin
- cortisone
- cosibelimab
- cosyntropin
- COVID-19 mRNA (Moderna) vaccine
- COVID-19 mRNA (Pfizer) vaccine
- crizotinib
- cyclophosphamide
- cyclosporine
- cytarabine
D
- dacarbazine
- daclizumab
- dactinomycin
- daratumumab
- dasatinib
- daunorubicin
- daunorubicin liposomal
- decitabine
- deflazacort
- denileukin diftitox
- deucravacitinib
- dexamethasone
- dimethyl fumarate
- dinutuximab
- diroximel fumarate
- docetaxel
- dostarlimab
- doxorubicin
- doxorubicin liposomal
- durvalumab
- duvelisib
E
- efalizumab
- efgartigimod alfa
- eflornithine
- elivaldogene autotemcel
- elotuzumab
- elranatamab
- enfortumab vedotin
- epcoritamab
- epirubicin
- eribulin
- etanercept
- etoposide
- etrasimod
- everolimus
- exagamglogene autotemcel
F
- fam-trastuzumab deruxtecan
- fexinidazole
- fingolimod
- floxuridine
- fludarabine
- fludrocortisone
- fluorouracil
- fruquintinib
G
H
I
- ibritumomab
- ibrutinib
- idarubicin
- idecabtagene vicleucel
- idelalisib
- ifosfamide
- imatinib
- imetelstat
- inavolisib
- inebilizumab
- infliximab
- influenza virus vaccine, h1n1, live
- influenza virus vaccine, live
- inotuzumab ozogamicin
- interferon gamma-1b
- iobenguane I 131
- iodine i 131 tositumomab
- ipilimumab
- irinotecan
- irinotecan liposomal
- isatuximab
- ixabepilone
- ixazomib
- ixekizumab
L
- leflunomide
- lenalidomide
- leniolisib
- levamisole
- lifileucel
- lisocabtagene maraleucel
- lomustine
- loncastuximab tesirine
- lovotibeglogene autotemcel
- lurbinectedin
- lutetium lu 177 dotatate
- lutetium lu 177 vipivotide tetraxetan
- lymphocyte immune globulin, anti-thy (equine)
M
- mechlorethamine
- melphalan
- melphalan flufenamide
- mercaptopurine
- methotrexate
- methylprednisolone
- midostaurin
- mirikizumab
- mitomycin
- mitoxantrone
- mogamulizumab
- momelotinib
- monomethyl fumarate
- muromonab-cd3
- mycophenolate mofetil
- mycophenolic acid
N
O
- obecabtagene autoleucel
- obinutuzumab
- ocrelizumab
- ofatumumab
- olaparib
- olaratumab
- omacetaxine
- osimertinib
- oxaliplatin
- ozanimod
P
- paclitaxel
- paclitaxel protein-bound
- pacritinib
- palbociclib
- panobinostat
- pazopanib
- pegaspargase
- pembrolizumab
- pemetrexed
- pentostatin
- pirtobrutinib
- plicamycin
- polatuzumab vedotin
- pomalidomide
- ponatinib
- ponesimod
- pralatrexate
- prednisolone
- prednisone
- procarbazine
Q
R
- retifanlimab
- revumenib
- ribociclib
- rilonacept
- risankizumab
- ritlecitinib
- rituximab
- romidepsin
- rozanolixizumab
- rucaparib
- ruxolitinib
S
- sacituzumab govitecan
- sarilumab
- sars-cov-2 (covid-19) ad26 vaccine, recombinant
- sars-cov-2 (covid-19) chadox1 vaccine, recombinant
- sars-cov-2 (covid-19) mrna-lnp vaccine (cvx 308)
- sars-cov-2 (covid-19) mrna-lnp vaccine (cvx 309)
- sars-cov-2 (covid-19) mrna-lnp vaccine (cvx 310)
- sars-cov-2 (covid-19) nvx-cov2373 vaccine, recombinant
- sars-cov-2 (covid-19) rs-nanoparticle vaccine, recombinant
- sars-cov-2 mrna (tozinameran 5y-11y) vaccine
- sars-cov-2 mrna (tozinameran 6m-4y) vaccine
- sars-cov-2 mrna (tozinameran-tris-sucrose) vaccine
- sars-cov-2 mrna (tozinameran) vaccine
- sars-cov-2 mrna-1273 (6m-5y) vaccine
- sars-cov-2 mrna-1273 (6y-11y) vaccine
- sars-cov-2 mrna-1273 (booster only) vaccine
- sars-cov-2 nvx-cov2373 vaccine, recomb (cvx 313)
- sars-cov-2 pres dtm (booster only) vaccine, recombinant
- satralizumab
- selinexor
- siltuximab
- siponimod
- sirolimus
- sirolimus protein-bound
- sirolimus topical
- spesolimab
- streptozocin
T
- tacrolimus
- tafasitamab
- talazoparib
- talquetamab
- tarlatamab
- tazemetostat
- teclistamab
- temozolomide
- temsirolimus
- teniposide
- teplizumab
- teriflunomide
- thalidomide
- thioguanine
- thiotepa
- tildrakizumab
- tisagenlecleucel
- tislelizumab
- tisotumab vedotin
- tocilizumab
- tofacitinib
- topotecan
- toripalimab
- tositumomab
- trabectedin
- trastuzumab
- tremelimumab
- treosulfan
- triamcinolone
- triamcinolone ophthalmic
- trimetrexate
U
V
- vamorolone
- vedolizumab
- venetoclax
- vinblastine
- vincristine
- vincristine liposome
- vinorelbine
- voclosporin
Z
Tick-borne encephalitis (inactivated) vaccine disease interactions
There is 1 disease interaction with tick-borne encephalitis (inactivated) vaccine which include:
Report options
QR code containing a link to this page
More about tick-borne encephalitis (inactivated) vaccine
- tick-borne encephalitis (inactivated) vaccine consumer information
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- Drug class: viral vaccines
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
